Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver

Drug Metabolism and Disposition

Volumn 40, Issue 5, 2012, Pages 902-906

  Sato, Yuichiro ^a   Miyashita, Aiji ^a   Iwatsubo, Takafumi ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENYLPHOSPHATASE; CARBOXYLESTERASE; CLOPIDOGREL; IRINOTECAN; LOPERAMIDE; NORDIHYDROGUAIARETIC ACID; OXYBUTYNIN; PHYSOSTIGMINE; PROCAINAMIDE;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HYDROLYSIS; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LIVER; LIVER CYTOSOL; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOTRANSFORMATION; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; LIVER; MANDELIC ACIDS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; TANDEM MASS SPECTROMETRY;

EID: 84859899711     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043208     Document Type: Article

References (28)

1. Abramov Y and Sand PK (2004) Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin Pharmacother 5:2351-2359. (Pubitemid 39489987)
2. Appell RA, Chancellor MB, Zobrist RH, Thomas H, and Sanders SW (2003) Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 78:696-702. (Pubitemid 36665899)
3. Eng H, Niosi M, McDonald TS, Wolford A, Chen Y, Simila ST, Bauman JN, Warmus J, and Kalgutkar AS (2010) Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor. Xenobiotica 40:369-380.
4. Farid NA, Kurihara A, and Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50:126-142.
5. Godin SJ, Crow JA, Scollon EJ, Hughes MF, DeVito MJ, and Ross MK (2007) Identification of rat and human cytochrome P450 isoforms and a rat serum esterase that metabolize the pyrethroid insecticides deltamethrin and esfenvalerate. Drug Metab Dispos 35:1664-1671. (Pubitemid 47296062)
6. Guay DR (2003) Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 42:1243-1285.
7. Haaz MC, Rivory LP, Riché C, and Robert J (1997) The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 356:257-262. (Pubitemid 27341982)
8. Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, and Ikeda T (2009) A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 37:2145-2152.
9. Heymann E and Krisch K (1967) [Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases]. Hoppe Seylers Z Physiol Chem 348:609-619.
10. Hosokawa M (2008) Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13:412-431.
11. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, and Satoh T (1995) Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 23:1022-1027.
12. Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Koyano N, Fujii A, Nagahara Y, Satoh T, and Chiba K (2007) Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes. Drug Metab Rev 39:1-15.
13. Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173-185.
14. Mizushima H, Takanaka K, Abe K, Fukazawa I, and Ishizuka H (2007) Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica 37:59-73. (Pubitemid 46009557)
15. Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, and Bosron WF (2005) Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313:1011-1016. (Pubitemid 40727004)
16. Rivory LP, Bowles MR, Robert J, and Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111. (Pubitemid 26338269)
17. Ross MK and Crow JA (2007) Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 21:187-196. (Pubitemid 350194379)
18. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, and Nagai E (1994) Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664. (Pubitemid 24186112)
19. Schegg KM and Welch W Jr (1984) The effect of nordihydroguaiaretic acid and related lignans on formyltetrahydrofolate synthetase and carboxylesterase. Biochim Biophys Acta 788:167-180. (Pubitemid 14031376)
20. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477-1484.
21. Slatter JG, Su P, Sams JP, Schaaf LJ, and Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164. (Pubitemid 27446586)
22. Takahashi S, Katoh M, Saitoh T, Nakajima M, and Yokoi T (2008) Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. J Pharm Sci 97:5434-5445.
23. Takahashi S, Katoh M, Saitoh T, Nakajima M, and Yokoi T (2009) Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos 37:956-961.
24. Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, Tatematsu M, and Hirano K (1997) Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 20:869-873. (Pubitemid 27382753)
25. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan B (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467-1476.
26. Wang J, Williams ET, Bourgea J, Wong YN, and Patten CJ (2011) Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2. Drug Metab Dispos 39:1329-1333.
27. Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611. (Pubitemid 34856347)
28. Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, et al. (2006) Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 21:147-155.